Logo Revvity

Revvity (RVTY) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Revvity · Health Care · ref. ETF XLV · 50 calls · price $129.71
🏆JPI 2026 portfoliosSee tracking →
What the company does: Revvity, Inc. provides health sciences solutions, technologies, and services.

📈 Revvity (RVTY) stock price

$129.71+45.4% over range
Aug 28, 25low $82.26 · high $129.71Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
43% recommend buying · 7 analysts
📊 JPI status : Revvity has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.

🎯 RVTY price target & analyst consensusprice $130

The price target · all analysts combined (7 targets)
Highest target · 1 firm of 7$126-2.9%
Median target · of 7 targets$105-19.1%
Lowest target · 1 firm of 7$90-30.6%
Current price$129.71
Where these 7 targets sit · versus the current price · 1 target per firm, last 6 months
Below 7100% $90 ↔ $126
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

The consensus · 7 ratings (last 6 months)
Strong Buy00%
Buy343%
Hold457%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Revvity? The JPI assistant answers using our backtest data.

💰 Revvity dividend: yield, history & growth › open the full page

0.25%annual yield
That's ~$0.28 per share per year.

📈 Revvity fundamentals: valuation, margins & growth › open the full page

P/E 62.4Net margin 8.2 %Revenue growth +1.3 %Very high P/E

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 13 %
2023
Rev −40%Profit +20%
2024
Rev +0%Profit −61%
2025
Rev +4%Profit −11%

🔎 Detailed analyses

🏛️ Which US Congress members hold Revvity (RVTY)?

3 Congress members have disclosed RVTY buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Gilbert Cisneros · 48%Rob Bresnahan · 31%Lisa McClain
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on RVTY

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Evercore ISI Group  100% +7.0% 2
Keybanc  67% +15.2% 3
Goldman Sachs  50% +18.2% 2
B of A Securities  50% -0.1% 2
Bernstein  50% -7.0% 2
Raymond James  44% +3.5% 9
Baird  20% -8.8% 5
Leerink Partners  0% -12.1% 2
Barclays  0% -13.3% 4
TD Cowen  0% -22.6% 3

📊 What $1,000 invested in Revvity would be worth › open the full page

In short — $1,000 invested in Revvity 10 years ago would be worth $2,303 today, i.e. +9%/yr on average. Best year: 2020 (+59%), worst: 2023 (-22%). Price performance, excluding dividends.

If I'd invested $1,000 in Revvity

InvestmentWorth todayGain
1 years ago$882-12%
3 years ago$809-19%
5 years ago$757-24%
→ See Revvity's full return history + gain calculator

Return by year (Revvity)

YearReturn$1,000 invested at year start
2026 (YTD)+2%$1,023 (+2%)
2025-14%$882 (-12%)
2024+18%$1,038 (+4%)
→ See Revvity's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Revvity

Loading news…

📋 All analyst calls on RVTY

▲ Outperform · 🎯$126
Price at call : $114.24 — upside +10%
Today : $129.71 — upside -3%
🎯 on RVTY : 100% (1 call matured) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Aug 5, 27
▲ Outperform · 🎯$125
Price at call : $112.05 — upside +12%
Today : $129.71 — upside -4%
🎯 on RVTY : 100% (1 call matured) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Jul 6, 27
Barclays 
May 7, 26
■ Equal-Weight neutral · not a buy · 🎯$105
Price at call : $101 — gap to target +4%
Today : $129.71 — gap to target -19%
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : May 7, 27
JP Morgan 
May 6, 26
■ Neutral neutral · not a buy · 🎯$90
Price at call : $98.85 — gap to target -9%
Today : $129.71 — gap to target -31%
🎯 on RVTY : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : May 6, 27
TD Cowen 
May 6, 26
▲ Buy · 🎯$120
Price at call : $98.85 — upside +21%
Today : $129.71 — upside -7%
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : May 6, 27
Stifel 
May 6, 26
■ Hold neutral · not a buy · 🎯$100
Price at call : $98.85 — gap to target +1%
Today : $129.71 — gap to target -23%
🎯 on RVTY : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : May 6, 27
Baird 
May 4, 26
▲ Outperform · 🎯$125
Price at call : $86.51 — upside +44%
Today : $129.71 — upside -4%
🎯 on RVTY : 33% (3 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : May 4, 27
Goldman Sachs 
Apr 14, 26
■ Neutral neutral · not a buy · 🎯$95
Price at call : $92.9 — gap to target +2%
Today : $129.71 — gap to target -27%
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Apr 14, 27
See the other 42 calls, newest to oldest
Barclays 
Apr 14, 26
■ Equal-Weight neutral · not a buy · 🎯$95
Price at call : $93.51 — gap to target +2%
Today : $129.71 — gap to target -27%
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 14, 27
JP Morgan 
Mar 31, 26
■ Neutral neutral · not a buy · 🎯$96
Price at call : $87.92 — gap to target +9%
Today : $129.71 — gap to target -26%
🎯 on RVTY : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Mar 31, 27
JP Morgan 
Feb 3, 26
■ Neutral neutral · not a buy · 🎯$105
Price at call : $103.83 — gap to target +1%
Today : $129.71 — gap to target -19%
🎯 on RVTY : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Feb 3, 27
TD Cowen 
Feb 3, 26
▲ Buy · 🎯$124
Price at call : $103.83 — upside +19%
Today : $129.71 — upside -4%
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Feb 3, 27
▲ Outperform · 🎯$118
Price at call : $101.13 — upside +17%
Today : $129.71 — upside -9%
🎯 on RVTY : 100% (1 call matured) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Feb 3, 27
Wells Fargo 
Feb 3, 26
■ Equal-Weight neutral · not a buy · 🎯$110
Price at call : $101.13 — gap to target +9%
Today : $129.71 — gap to target -15%
🎯 on RVTY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 3, 27
Barclays 
Feb 3, 26
▲ Overweight · 🎯$118
Price at call : $101.13 — upside +17%
Today : $129.71 — upside -9%
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 3, 27
Jefferies 
Feb 3, 26
■ Hold neutral · not a buy · 🎯$105
Price at call : $101.13 — gap to target +4%
Today : $129.71 — gap to target -19%
🎯 on RVTY : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Feb 3, 27
Barclays 
Dec 15, 25
▲ Overweight · 🎯$115
Price at call : $96.27 — upside +19%
Today : $129.71 — upside -11%
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Dec 15, 26
Wells Fargo 
Dec 15, 25
■ Equal-Weight neutral · not a buy · 🎯$107
Price at call : $96.27 — gap to target +11%
Today : $129.71 — gap to target -18%
🎯 on RVTY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 15, 26
Goldman Sachs 
Dec 9, 25
■ Neutral neutral · not a buy · 🎯$105
Price at call : $98.78 — gap to target +6%
Today : $129.71 — gap to target -19%
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Dec 9, 26
Barclays 
Oct 28, 25
▲ Overweight · 🎯$105
Price at call : $96.45 — upside +9%
Today : $129.71 — upside -19%
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 28, 26
Baird 
Oct 28, 25
▲ Outperform · 🎯$123
Price at call : $96.45 — upside +28%
Today : $129.71 — upside -5%
🎯 on RVTY : 33% (3 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Oct 28, 26
Guggenheim 
Oct 16, 25
■ Neutral neutral · not a buy
🎯 on RVTY : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Oct 16, 26
▲ Outperform · 🎯$106
Price at call : $91.77 — upside +16%
Today : $129.71 — upside -18%
🎯 on RVTY : 100% (1 call matured) · 📊 on Health : 45.8% · +0.0% (168 calls)
in progress (365j)
matures : Oct 7, 26
Barclays 
Oct 2, 25
▲ Overweight · 🎯$100
Price at call : $91.46 — upside +9%
Today : $129.71 — upside -23%
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Oct 2, 26
▲ Buy · 🎯$99
Price at call : $85.71 — upside +16%
Today : $129.71 — upside -24%
🎯 on RVTY : 50% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Sep 22, 26
Raymond James 
Jul 29, 25
▲ Outperform · 🎯$115
Price at call : $90.85 — upside +27%
Today : $129.71 — upside -11%
Expected +27% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on RVTY : 20% (5 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
+25.0%
stock +25% · XLV +22%
matured Jul 29, 26
Stifel 
Jul 29, 25
■ Hold neutral · not a buy · 🎯$110
Price at call : $94.47 — gap to target +16%
Today : $129.71 — gap to target -15%
🎯 on RVTY : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Jul 29, 26
▲ Outperform · 🎯$115
Price at call : $100.66 — upside +14%
Today : $129.71 — upside -11%
Expected +14% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 100% (1 call matured) · 📊 on Health : 45.8% · +0.0% (168 calls)
+8.6%
stock +9% · XLV +20%
matured Jul 8, 26
▲ Buy · 🎯$110
Price at call : $97.82 — upside +12%
Today : $129.71 — upside -15%
Expected +12% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 50% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
+13.7%
stock +14% · XLV +20%
matured Jun 26, 26
UBS 
May 1, 25
▲ Buy · 🎯$115
Price at call : $92.9 — upside +24%
Today : $129.71 — upside -11%
Expected +24% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 51.5% · +3.1% (355 calls)
-6.7%
stock -7% · XLV +6%
matured May 1, 26
Goldman Sachs 
Apr 29, 25
▲ Buy · 🎯$125
Price at call : $93.43 — upside +34%
Today : $129.71 — upside -4%
Expected +34% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 50.8% · +2.0% (240 calls)
-7.3%
stock -7% · XLV +4%
matured Apr 29, 26
JP Morgan 
Apr 29, 25
■ Neutral neutral · not a buy · 🎯$100
Price at call : $93.43 — gap to target +7%
Today : $129.71 — gap to target -23%
🎯 on RVTY : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Apr 29, 26
Raymond James 
Apr 29, 25
▲ Outperform · 🎯$120
Price at call : $93.43 — upside +28%
Today : $129.71 — upside -7%
Expected +28% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 20% (5 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-7.3%
stock -7% · XLV +4%
matured Apr 29, 26
Baird 
Apr 29, 25
▲ Outperform · 🎯$125
Price at call : $94.66 — upside +32%
Today : $129.71 — upside -4%
Expected +32% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 33% (3 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
-13.1%
stock -13% · XLV +3%
matured Apr 29, 26
Baird 
Apr 21, 25
▲ Outperform · 🎯$127
Price at call : $89.77 — upside +41%
Today : $129.71 — upside -2%
Expected +41% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 33% (3 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
+5.0%
stock +5% · XLV +10%
matured Apr 21, 26
Wells Fargo 
Apr 17, 25
■ Equal-Weight neutral · not a buy · 🎯$102
Price at call : $89.77 — gap to target +14%
Today : $129.71 — gap to target -21%
🎯 on RVTY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Apr 17, 26
Barclays 
Apr 10, 25
▲ Overweight · 🎯$110
Price at call : $94.86 — upside +16%
Today : $129.71 — upside -15%
Expected +16% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
-2.3%
stock -2% · XLV +8%
matured Apr 10, 26
Barclays 
Feb 3, 25
▲ Overweight · 🎯$140
Price at call : $123.16 — upside +14%
Today : $129.71 — upside +8%
Expected +14% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
-15.7%
stock -16% · XLV +6%
matured Feb 3, 26
Raymond James 
Feb 3, 25
▲ Outperform · 🎯$145
Price at call : $123.69 — upside +17%
Today : $129.71 — upside +12%
Expected +17% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 20% (5 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-18.2%
stock -18% · XLV +5%
matured Feb 3, 26
Keybanc 
Feb 3, 25
▲ Overweight · 🎯$145
Price at call : $123.69 — upside +17%
Today : $129.71 — upside +12%
Expected +17% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 44.1% · -1.7% (143 calls)
-18.2%
stock -18% · XLV +5%
matured Feb 3, 26
Raymond James 
Jan 21, 25
▲ Outperform · 🎯$140
Price at call : $122.78 — upside +14%
Today : $129.71 — upside +8%
Expected +14% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 20% (5 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-4.1%
stock -4% · XLV +11%
matured Jan 21, 26
▲ Buy · 🎯$138
Price at call : $115.17 — upside +20%
Today : $129.71 — upside +6%
Expected +20% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 50% (2 calls matureds) · 📊 on Health : 48.3% · +2.0% (356 calls)
-14.0%
stock -14% · XLV +12%
matured Dec 13, 25
Barclays 
Nov 25, 24
▲ Overweight · 🎯$135
Price at call : $115.07 — upside +17%
Today : $129.71 — upside +4%
Expected +17% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
-9.0%
stock -9% · XLV +8%
matured Nov 25, 25
TD Cowen 
Nov 5, 24
▲ Buy · 🎯$144
Price at call : $124.86 — upside +15%
Today : $129.71 — upside +11%
Expected +15% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 49% · +1.0% (96 calls)
-28.3%
stock -28% · XLV -1%
matured Nov 5, 25
Bernstein 
Nov 5, 24
▲ Outperform · 🎯$145
Price at call : $124.86 — upside +16%
Today : $129.71 — upside +12%
Expected +16% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 54.7% · +5.2% (64 calls)
-28.3%
stock -28% · XLV -1%
matured Nov 5, 25
Raymond James 
Nov 5, 24
▲ Outperform · 🎯$146
Price at call : $124.86 — upside +17%
Today : $129.71 — upside +13%
Expected +17% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 20% (5 calls matureds) · 📊 on Health : 46.5% · +1.6% (402 calls)
-28.3%
stock -28% · XLV -1%
matured Nov 5, 25
Baird 
Nov 5, 24
▲ Outperform · 🎯$138
Price at call : $125.96 — upside +10%
Today : $129.71 — upside +6%
Expected +10% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 33% (3 calls matureds) · 📊 on Health : 51.7% · +6.5% (298 calls)
-26.5%
stock -27% · XLV -1%
matured Nov 5, 25
▲ Outperform · 🎯$135
Price at call : $119.67 — upside +13%
Today : $129.71 — upside +4%
Expected +13% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
-20.4%
stock -20% · XLV -5%
matured Oct 17, 25
Barclays 
Oct 15, 24
▲ Overweight · 🎯$140
Price at call : $124.36 — upside +13%
Today : $129.71 — upside +8%
Expected +13% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RVTY : 0% (4 calls matureds) · 📊 on Health : 50.1% · +2.2% (629 calls)
-25.9%
stock -26% · XLV -7%
matured Oct 15, 25
Wells Fargo 
Aug 27, 24
■ Equal-Weight neutral · not a buy · 🎯$130
Price at call : $121.29 — gap to target +7%
Today : $129.71 — gap to target +0%
🎯 on RVTY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 27, 25

Frequently asked questions

Should I buy Revvity stock?

This isn't buy advice. For Revvity, the analyst consensus is "Hold", with an average price target of $105 (-19% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Revvity). We show the numbers — you decide.

Is it too late to buy Revvity? How high can it go?

The most bullish analyst target on Revvity is $126 (-3% above today's price); the average is $105. That's the upside they see. Check how reliable those analysts have actually been on Revvity on our site before trusting it.

Is Revvity still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 10 analysts have a real record on Revvity, the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.

Should you invest in Revvity? The case for and against

The arguments for and against, one by one, from the numbers: why invest in RVTY (and why hesitate).

What has Revvity's past performance been?

Historical returns and a "how much if I had invested" calculator: RVTY performance & returns.

Does Revvity pay a dividend?

Yield, consistency and growth history of the dividend: RVTY's dividend.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)